Investment Summary

The BroadOak Fund Invests In CDI Laboratories

On January 9, 2023, growth capital firm The BroadOak Fund invested in life science company CDI Laboratories

Investment Highlights
  • This is The BroadOak Fund’s 20th transaction in the Life Science sector.
  • This is The BroadOak Fund’s 1st transaction in Puerto Rico.

Investment Summary
Date 2023-01-09
Target CDI Laboratories
Sector Life Science
Investor(s) The BroadOak Fund
Deal Type Growth Capital

Target

CDI Laboratories

Mayaguez, Puerto Rico
CDI Laboratories is the nextGen proteomics company, a result of intensive efforts and advances made by synthetic biologists at the Johns Hopkins University School of Medicine. The company was created by scientists for scientists to address critical needs required accelerate research, advance discoveries, and translate these discoveries into novel products and services that improve human health. CDI Laboratories is based in Mayaguez, Puerto Rico.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

The BroadOak Fund

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Size Small
Type Sector Focused
DESCRIPTION

The BroadOak Fund is the investment affiliate of life science focused investment bank BroadOak Capital Partners. The BroadOak Fund provides growth capital to life sciences tools and service providers that have achieved a level of commercial success. The BroadOak Fund is based in Bethesda, Maryland.

DEAL STATS #
Overall 25 of 25
Sector (Life Science) 20 of 20
Type (Growth Capital) 14 of 14
Country (Puerto Rico) 1 of 1
Year (2023) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-09 Sanguine BioSciences

Woburn, Massachusetts, United States

Sanguine BioSciences engages in-home specimen collection and a leader in direct-to-patient recruitment and digital health innovation. Sanguine BioSciences bridging the gap between patients and researchers to accelerate discovery and development. Sanguine BioSciences is based in Woburn, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-01-23 Emvenio Research

Durham, North Carolina, United States

Emvenio Research is a decentralized research organization (DRO) providing scalable and hybrid decentralized trial solutions with a focus on improving access and health equity in clinical research. Emvenio Research is based in Durham, North Carolina.

Sell -
Mergr

Product

Company

Legal